Anupam Rasayan India Limited
Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.
What Anupam files
- Others71
- Investor Meet34
- Updates30
- Board Meeting15
- PPTs10
- Important9
Anupam Rasayan has approved acquiring 2,60,065 equity shares of Tanfac Industries via a preferential issue for Rs. 60.88 Cr. This move aims to restore stake dilution following Tanfac's QIP, strengthening the company's position in fluorine chemistry without related party transaction hurdles.
Anupam Rasayan secured a six-year specialty chemical supply contract with a US-based global industrial major, marking a significant expansion into a new segment.
Anupam Rasayan Q1FY27 consolidated revenue grew 36% YoY to Rs 667.5 Cr, with EBITDA up 35% to Rs 174.9 Cr. PAT rose 6% to Rs 51.2 Cr. Achieved ETFA commercialization milestone. Signed US$300 million LoI with BASQUEVOLT. Bliss GVS Pharma acquisition progressing.
Anupam Rasayan announced an open offer to acquire 26% of Bliss GVS Pharma for ₹829.03 Cr at ₹299/share. This follows an agreement to buy 43.11% from sellers, making Anupam Rasayan the new promoter with plans to streamline operations.
Anupam Rasayan acquired Mates Visa Consultancy for INR 10,000, making it a wholly-owned subsidiary. This strategic acquisition is for group restructuring and supports the planned acquisition of Bliss GVS Pharma. Mates Visa's business objects are being amended to align with Anupam Rasayan's, with FY26 turnover of 0.31 Cr.